[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
July 1983

The Clinical Course of End-Stage Renal Disease in Systemic Lupus Erythematosus

Author Affiliations

From the Department of Medicine, Sections of Arthritis and Connective Tissue Disease (Dr Jarrett) and Nephrology (Drs Santhanam and Del Greco), Northwestern University Medical School, Chicago. Dr Jarrett is currently with the Department of Medicine, Division of Rheumatology, State University of New York Downstate Medical Center.

Arch Intern Med. 1983;143(7):1353-1356. doi:10.1001/archinte.1983.00350070073014

• Despite treatment advances, renal failure still develops in patients with systemic lupus erythematosus (SLE). With the common use of long-term maintenance hemodialysis, this complication is no longer fatal. In order to evaluate factors that contribute to the outcome of patients with SLE receiving long-term hemodialysis, we retrospectively analyzed the clinical course of 14 patients with SLE receiving hemodialysis for more than three months, and compared them with 62 patients receiving long-term hemodialysis who did not have SLE. While receiving long-term hemodialysis, SLE activity was minimal, with most manifestations involving the CNS or synovitis. Five-year survival was significantly lower in the SLE than in the non-SLE group (58.6% v 88.5%), but no deaths were directly attributable to SLE activity. Morbidity in the SLE group was primarily due to infection and vascular access problems.

(Arch Intern Med 1983;143:1353-1356)